Epilepsy is a general term used to describe a collection of common, Prior to the recent influx of nearly two dozen AEDs to the pharmacopeia, treatment choices in epilepsy were fairly straightforward, but arguably limited. Today, the decision as to which AED to administer can be a daunting task given the sheer number of AEDs available, lack of headto-head drug comparisons, and the staggering array of patient-specific variables that physicians must consider when choosing an appropriate treatment regimen. Among the many factors that can affect response to AEDs are the type of seizure, disease stage, prior and current AED
therapy, age, concomitant medications, and comorbid conditions. Given the serious nature of epilepsy and the complexity of the drugs currently available to treat it, prescribing AEDs using only a trial-and-error approach may not be the best strategy. Thus, a more sophisticated method for treatment decisions is desirable in order to meet individual patient needs and to optimize patient outcome.
Not all AEDs are effective for both focal (partial-onset) and generalized seizures, and one of the most important factors in choosing an AED is the type of seizure and epilepsy syndrome being treated. 5 While focal seizures overall are successfully managed with the recently approved AEDs, an important subset of patients remain refractory to treatment. 5 Almost all of the second-and third-generation AEDs have been approved based on their efficacy and safety as adjunctive treatment for focal seizures. 6, 7 Thus, most of the data available for comparative evaluations of the newer AEDs are from trials in which patients were already taking at least one AED (with or without concurrent use of vagus nerve stimulation).
This review will consider evidence that can affect treatment decisions for focal epilepsies. Generalized epilepsies and treatment decisions for generalized seizures (including absence, myoclonic, and tonic-clonic seizures, as well as
Lennox-Gastaut or West syndromes) will not be discussed.
What to Compare-What Matters When We Choose an Antiepileptic Drug?
Randomized clinical trials (RCTs) are designed to assess the efficacy, tolerability, and safety of a particular drug compared with placebo within the strict confines of an a priori-defined study design. As such, results from drug trials can fail to answer common clinical questions. 8, 9 While efficacy is naturally the most important factor when choosing an AED, it exists in partnership with many other factors, all of which can contribute to drug effectiveness-how a treatment works under ordinary conditions, administered by the typical practitioner to the typical patient. To guide treatment decisions, physicians need some indication as to how efficacious one AED can be compared with another (or in combination with another) while being mindful of patient-and drug-specific variables that can influence treatment success, including safety and tolerability, drug-drug interactions, dosing, and cost.
Rational Polytherapy
The explosion of a variety of new AEDs to the market in recent years has renewed interest in combination therapy for epilepsy, particularly for patients who are not adequately controlled with a single AED. Though monotherapy is considered the standard of care for patients with newly diagnosed epilepsy, treatment with two or more AEDs has been shown to be effective in patients who do not achieve adequate seizure control following sequential monotherapy. 10 The term 'rational polytherapy' (or 'polypharmacy') has been used to describe the careful selection of drug combinations intended to improve overall treatment effect without added drug toxicity. 11 In practice, implementing rational polytherapy can be quite challenging as evidence from prospective trials designed to identify optimal AED combinations is lacking. However, given the roughly 200 two-drug combinations and >1,000 three-drug combinations that are possible with currently available AEDs, prospective comparative efficacy trials are impractical and costprohibitive. 11 Most of what is currently known about particular AED combinations has been derived from clinical experience or gleaned from retrospective and post hoc exploratory analyses.
The decision to add a drug to a treatment regimen rather than pursue sequential monotherapy can have several advantages, including the potential for synergistic effects. Because of the successful combination of drugs with differing mechanisms of action (MOA) for a number of other diseases (e.g.,
Alzheimer's disease, HIV, diabetes), a similar approach for epilepsy seems logical, and one would expect greater likelihood of synergistic effects when combining
AEDs with different MOAs. While clinical and preclinical evidence suggests that drug effectiveness can be increased by combining a sodium-channel blocking AED with a drug that enhances GABAergic neurotransmission, the only AED combination that has shown a synergistic effect to date is lamotrigine (LTG) combined with valproate (VPA). 2, 12, 13 Moreover, the efficacy of two or more sodium-channel blocking AEDs combined may not be more efficacious than each drug alone. 2 Table 1 ). Vigabatrin (VGB) (Sabril ® ) and ezogabine (EZG)/retigabine (Potiga ® /Trobalt ® ) are considered 'last resort' drugs, and are therefore not included in Table 1 . VGB is indicated as adjunctive therapy only in patients with complex partial seizures who are unresponsive to treatment with other AEDs and for whom the risk for vision loss with VGB treatment outweighs the perceived benefits. 44 EZG has also been linked with retinal abnormalities, potential vision loss, and blue skin discoloration; 45 it is currently unknown if the skin discoloration or retina pigmentation changes are reversible. 46 The efficacy of the newer AEDs for refractory focal seizures has been compared in recently published systematic reviews and meta-analyses (see Table 1 ). 47 In the absence of head-to-head trials, indirect comparisons of AED efficacy can be used to guide clinical decisions. Results from a random-effects metaanalysis (based on relative measurements of treatment effect) showed significant differences in responder rates favoring TPM over the pooled net effect of the other AEDs; the least efficacious AEDs were GBP and LCM. 47 When adjusted for baseline risk, TPM and LEV were most efficacious, while GBP and TGB were least efficacious. Gao et al. 48 used a similar methodology to indirectly compare responder rates among the AEDs tested and found that ESL and BRV were the most efficacious; however, at the time of this publication BRV has not received FDA approval. 48 Though it may be convenient to take these results at face value, such indirect comparisons can be complicated by many factors. In a systematic review and meta-analysis evaluating the possible effects of methodological differences in trial design and analyses on AED efficacy comparisons, it was determined that indirect efficacy comparisons are confounded by several factors, 
Seizure Freedom
The ultimate goal of AED treatment is seizure freedom. Seizure freedom is often reported as the proportion of seizure-free patients or the proportion of seizure-free days during treatment. Since the analysis of seizure freedom is and may be difficult due to methodological differences. With these caveats in mind, seizure freedom rates among several AEDs have been compared using a 'pragmatic intent-to-treat (ITT)' approach. 50 Gazzola et al. found that seizure freedom rates (proportion of seizure-free patients) among those treated with OXC, GBP, LTG, LEV, PGB, and ZNS were low, ranging from ≤1.0 % (ZNS, LTG) to 6.4 % (LEV). 50 Using an LOCF approach, seizure freedom rates in the same trials were found to be falsely inflated, serving as an example of the complexity and difficulty of such comparisons. 50 Of the newer AEDs for which seizure freedom is reported in the pivotal trials, PGB has the highest rate versus placebo, followed by OXC, TPM, and LEV (see Table 1 ).
In the same random-effects meta-analysis described above, seizure freedom rates (available for 32 of 63 studies) showed no significant differences among the AEDs tested, but all AEDs had a more favorable response than placebo. By combining indirect and direct evidence from eight head-tohead trials, comparisons of seizure freedom rates favored TPM over LTG, while no differences were detected between LTG and either PGB or LEV. 47 An additional meta-analysis found seizure freedom rates favoring all AEDs over placebo, with outcomes favoring LCM over ESL, EZG, CAR, BRV, and PMP. 48 Again, differences in parameters and assumptions can limit the ability to show a clinically meaningful difference in seizure freedom rates among the AEDs.
Taken together, direct and indirect comparisons indicate few if any differences in efficacy of one newer AED over another, underscoring the importance of other factors that contribute to drug effectiveness and treatment success.
Safety and Tolerability
Though efficacy varies little among the newer third-and second-generation AEDs-and is similar to the first generation AEDs (e.g., VPA, CBZ) 51 -the newer AEDs are often advantageous with respect to tolerability, having fewer side effects, and a lower risk for drug-drug and hypersensitivity interactions than older AEDs. 
Adverse Events
The potential for adverse events (AEs) with a particular AED may be a strong differentiating factor when making treatment decisions. Most AEs are manageable, only requiring dose adjustments or a change in drug formulation, e.g., from immediate-release to XR. Overall, the newer AEDs have few worrisome side effects. AEs most commonly associated with the newer AEDs are neurological or gastrointestinal effects, including dizziness, ataxia, somnolence, and nausea (see Table 2 ).
In addition to the common AEs identified in Table 2 , select 'Warnings and Precautions' that may further distinguish one AED over another are listed in Table 3 . Patients treated with ESL have had drug reaction with eosinophilia and systemic symptoms (DRESS), also known as multiorgan hypersensitivity; kidney stones can occur with TPM and ZNS; LEV 52 and PMP have been linked to psychiatric symptoms and behavioral issues; cognitive dysfunction or depression and mood problems have been reported with TPM; and weight gain with PGB, PMP, and GBP may be a differentiating factor. Not listed in Table 3 (since it appears in the prescribing information
[PI] for each AED and would therefore not be a distinguishing factor) are suicidality and the potential for increased seizure frequency with rapid withdrawal. Two of the newer AEDs also carry black box warnings on their labeling for rare and idiosyncratic reactions: LTG for serious skin rashes (including Stevens-Johnson syndrome and toxic epidermal necrolysis);
PMP for life-threatening psychiatric and behavioral reactions (including aggression, hostility, irritability, anger, and homicidal ideation). 53 In the random-effects meta-analysis, six pre-specified AEs were compared among the newer AEDs: ataxia, headache, dizziness, fatigue, nausea, and somnolence. Overall, few differences between AEDs were found: In addition to AE incidence, patient withdrawal due to AEs for a particular AED can be a good indicator of tolerability. Withdrawals due to AEs were greater than placebo for all AEDs. 47 Comparison of each AED to the pooled effect of the others revealed significantly fewer withdrawals due to AEs with LEV; no differences among the other AEDs were detected. 47 
Drug-Drug Interactions and Comorbidities
Important factors to consider when making treatment decisions for the patient with focal epilepsy are the risk for drug-drug interactions and the presence of comorbid conditions. AEDs are among the most complex class of drugs in terms of pharmacokinetic properties and are some of the leading medications responsible for drug-drug interactions. 54 Risk for drug interactions are especially high in the elderly, as most elderly epilepsy patients take an average of seven prescription medications. 55 As a group, the newer AEDs are less likely to cause adverse drug interactions because most do not induce the CYP450 enzyme system, the main culprit of drug-drug interactions (see Table 4 ). 54 This study and the data reported in specific PIs showed that most newer AEDs (GBP, LTG, LEV, OXC, PGB, TGB, TPM) have no effect on the drug plasma concentrations of older AEDs (CBZ, PB, PHT, primidone, VPA), with the exception of an increase Table 4 .
Since newer AEDs are equivalent or nearly equivalent in efficacy 58 without the risks associated with the older enzyme-inducing AEDs, prudence dictates that newer AEDs be used preferentially, reserving enzymeinducing AEDs as a last resort.
Pregnancy
The choice of AED for women of child-bearing age was once thought to be crucial given the known effects of VPA on fetal cognition 59 ), LEV (60 %-75 %), 62, 63 and TPM (40 %-60 %). 63 The greatest 2-year retention rates found were in patients treated with OXC (85 %) 64 and LTG (74 %). 65 Three-year retention was highest with LTG (74 %) followed by TPM (64 %), GBP (42 %), and TGB (38 %).
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Drug Administration-Titration, Dosing, and Drug Formulations
One of the most important reasons for low drug effectiveness is patient non-adherence to their treatment regimen. 67 Patients that are not fully adherent to their AED treatment regimen have increased seizures and higher rates of morbidity and mortality. [68] [69] [70] Poor adherence depends on several factors, including length of titration, dosing frequency, and drug formulation (tablet, capsule, liquid). There is little difference among AEDs in the time to reach steady-state/maintenance dose (~4 weeks) with the exception of LTG and TPM, both requiring up to 8 weeks titration depending on dose-escalation strategy. In general, increased dosing frequency means reduced treatment adherence. In a systematic review, 71 patient adherence was significantly greater with once-daily drug dosing versus three-and four-times daily dosing; a significant difference in adherence also was found in favor of twice-daily dosing versus fourtimes daily dosing, while no difference was detected between once-and twice-daily dosing.
Most patients prefer to take fewer daily doses of any medication. Extendedrelease (XR) or controlled-release (CR) drug formulations can simplify treatment and improve adherence by reducing dosing frequency, 72 though the overall number of daily tablets or capsules may not differ greatly from immediate-release (IR) AEDs that need to be dosed more frequently (see Table 5 ). XR AEDs can alleviate breakthrough seizures and AEs caused by fluctuating plasma concentrations and peak-dose toxicity 73 and may be preferable over IR formulations in patients who take drugs for other conditions. Newer AEDs that are available as XR formulations include LEV, LTG, OXC, and TPM. [74] [75] [76] [77] [78] Intravenous ( see Table 5 ).
AEDs are prescribed for off-label use more than any other drug class (74 % versus 60 % for antipsychotics and 41 % for antibiotics). Use of generic AEDs, when available, can offer tremendous cost savings to patients 80 (see Table 5 ), but it is important to understand that AEDs are US NEUROLOGY unlike other drug classes in that small differences between formulations can have serious consequences, including breakthrough seizures and toxic side effects. 81 Additionally, as generics only have to show bioequivalence to the branded drug, pharmacokinetic differences among generic products may also have serious consequences. Experts in the field recommend maintaining patients on a single generic manufacturer to minimize generic switching and the associated repercussions. 82, 83 The American Academy of Neurology (AAN) supports the use of the newer AEDs, but opposes generic substitution without attending physician approval. The AAN also opposes legislation requiring physicians to seek authorization prior to drug dispensing.
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The Bottom Line-What Really Differentiates and What Helps Clinicians Choose a Drug?
In the absence of large, observational studies to determine the long-term effectiveness of individual AEDs, clinicians must approach treatment decisions with a full perspective, considering and comparing the many factors that contribute to treatment success for an individual patient.
The overall differences in efficacy among the newer AEDs-and between newer and older AEDs-do not clearly separate one drug from another. This is true for other drug classes (such as anxiolytics, antidepressants, and antipsychotics) and also largely for neurostimulation (vagal nerve stimulation, deep brain stimulation, and responsive neurostimulation). 
Making Treatment Choices-Illustrative Cases from Our Practice
In order to provide real-life examples of the clinical challenges noted above, particularly for specialized populations, below are case reports from our practices that detail our thought processes in determining diagnosis and best course of treatment for these individual patients.
Case 1. Episodes in Pediatric Patient
Presentation A previously healthy 6-year-old boy fell asleep at his desk while at school.
His teacher woke him up, but he was disoriented. He felt numbness and tingling in the left side of his face, realized he had dropped a pen, went to pick it up and fell out of his chair. While on the ground, the teacher described him to be rigid, in a fetal position with clenched hands and teeth.
His eyes were rolled up, and he was drooling. This lasted approximately that is easy to take (and give by caregivers) with the fewest daily doses possible, will likely increase adherence to the prescribed treatment. As it was recently reported, early adherence to treatment could be an important factor in improving seizure outcomes. 84 When possible, monotherapy should be attempted. Yet, if the use of polytherapy is required to improve seizure control, the fewest number of combination drugs should be sought, as this will likely result in a lower risk for side effects. 
Diagnosis and Treatment
Considering all investigation results, mesial temporal lobe epilepsy of unknown origin was diagnosed.
Treatment was started with LEV. After slow titration up to 1,000 mg LEV, seizure frequency was reduced by 70 %. Due to skin allergy fears, LTG was not used, but a low dose of TPM up to 100 mg/d added; LEV in combination was reduced to 500 to 1,000 mg/d. Under this combination therapy the patient reported further improvement. Figure 1) . She also had a cluster of generalized absence seizures associated with generalized 3-4 Hz spike-and-wave discharges (see Figure 2) . LTG was then added, titrated to 100 mg bid, and LEV was reduced to 1,000 mg bid due to some jitteriness. She had no recurrence of generalized tonic-clonic seizures;
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however, 6 months later she reported small episodes of losing her conversation for a few seconds. We increased LTG to 300 then 400 mg per day. She has remained seizure free for at least 2 years.
Diagnosis and Treatment
The patient was diagnosed with idiopathic generalized epilepsy (IGE) with generalized absence and generalized tonic-clonic seizures. Versive head turning may have suggested focal onset, but is not unusual in primary generalized tonic-clonic seizures. 87 What the patient called partial seizures probably represented generalized absence seizures. IGE usually starts before age 20 but may occasionally start later, up to 5.7 % after age 30 in one study. 88 The diagnosis of generalized epilepsy helped in choosing a medication appropriate for generalized epilepsy, and avoiding medications that are specific for focal epilepsy. At onset, symptoms occurred once or twice a year, but subsequently increased in frequency to daily, sometimes occurring five times per day, often awakening him from sleep.
Ten years after onset of symptoms, he underwent extensive cardiac workup including 24-hour Holter monitor, which resulted in pacemaker placement, which had no effect on his symptoms, and was subsequently deactivated 1 year after placement. Before presentation at age 39, he was not treated with antiepileptic medications.
There was no history of febrile seizures or significant head trauma. The patient was the product of a normal pregnancy and delivery with normal developmental milestones.
Video EEG monitoring showed approximately 10 seizures per day, with associated signs of inattentiveness documented by inability to consistently follow simple commands, which often progressed to bilateral eyelid fluttering and mouthing movements. After the events, he was immediately conversant, and able to accurately recall his symptoms. With all events, there was a stereotypical associated bradycardia to 30-40 beats per minute, which began approximately 5 to 6 seconds after symptom onset, lasting 5 seconds before resolving. There were no inter-ictal epileptiform discharges.
There were associated ictal EEG changes, with some events showing diffuse, 7-8 Hz activity at the end of the event. Head CT was normal. MRI was contraindicated because of his pacemaker.
The patient started CBZ, titrating to a dose of 600 mg twice daily, with complete resolution of symptoms. He has remained seizure free for years since initiation of CBZ. 
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